Edmund Harrington

Novartis (Switzerland) — Switzerland

Medicine · Health Sciences

15h-index1.3kcitations23works8.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(5), Protein Degradation and Inhibitors(5), Chemical Synthesis and Analysis(3), Monoclonal and Polyclonal Antibodies Research(3), Chromatin Remodeling and Cancer(3)

Publications23 total

Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma
Cancers·2024· 8 citedOpen Access
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
Blood Cancer Journal·2022· 42 citedOpen Access
Chemoproteomics Enabled Discovery of Selective Probes for NuA4 Factor BRD8
ACS Chemical Biology·2021· 11 cited
Chemoproteomics Enabled Discovery of Selective Probes for NuA4 Factor BRD8
2021Open Access
Bile acid analogues are activators of pyrin inflammasome
Journal of Biological Chemistry·2019· 59 citedOpen Access
Previously Uncharacterized Vacuolar-type ATPase Binding Site Discovered from Structurally Similar Compounds with Distinct Mechanisms of Action
ACS Chemical Biology·2018· 15 cited
Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells
Scientific Reports·2017· 39 citedOpen Access
Additional file 1: of Examining the influence of specificity ligands and ATP-competitive ligands on the overall effectiveness of bivalent kinase inhibitors
Figshare·2017Open Access
Examining the influence of specificity ligands and ATP-competitive ligands on the overall effectiveness of bivalent kinase inhibitors
Proteome Science·2016· 7 citedOpen Access
Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy <i>in Vivo</i>
ACS Medicinal Chemistry Letters·2015· 51 citedOpen Access
Conversion of a Single Polypharmacological Agent into Selective Bivalent Inhibitors of Intracellular Kinase Activity
ACS Chemical Biology·2015· 27 citedOpen Access
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases
Journal of Medicinal Chemistry·2015· 87 cited
Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo
Nature Cell Biology·2014· 717 cited
Detecting S-adenosyl-l-methionine-induced conformational change of a histone methyltransferase using a homogeneous time-resolved fluorescence-based binding assay
Analytical Biochemistry·2012· 15 cited
Kinase Inhibitor Profiling Using Chemoproteomics
Methods in molecular biology·2011· 16 cited
The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor
ACS Medicinal Chemistry Letters·2011· 83 citedOpen Access
Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells
Blood·2011· 34 citedOpen Access
Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors
Bioorganic & Medicinal Chemistry Letters·2009· 45 citedOpen Access
Use of Ligand Based Models for Protein Domains To Predict Novel Molecular Targets and Applications To Triage Affinity Chromatography Data
Journal of Proteome Research·2009· 18 cited
Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK)
Bioorganic & Medicinal Chemistry Letters·2008· 28 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Markus Schirle(9), Jason R. Thomas(8), Iván Cornella‐Taracido(6), John A. Tallarico(5), Rishi K. Jain(5), Jason Murphy(5), Francesco G. Salituro(4), Xin Chen(4), William C. Forrester(4), John E. Cochran(3), Guy W. Bemis(3), Paul Taslimi(3), Carsten Russ(3), Alexia T. Kedves(3), Carrie M. Gower(3), Karen Ackermann(3), Ana M. García(3), Michael D. Lewis(3), Helen Trinh Pham(3), William E. Dowdle(2)